In these years, immune checkpoint therapy is striking in cancer therapy with advantages of durable responses and long-term survival. The clinical success show us that immune checkpoint therapy show advantages in various cancers, such as Lung and Kidney Cancers, Metastatic Melanoma.
The PD-1 immune checkpoint therapy inhibitor, Nivolumab given as a second-line to fifth-line treatment of lung cancer produced an overall response rate of 18% in 76 evaluable patients, "and of the responses, 20 of 31 lasted more than a year, and toxicity was quite mild, with all grade 3 or 4 events being 1% or less," said Gregory A. Otterson, MD, Professor of Internal Medicine, Ohio State University Comprehensive Cancer Center, Columbus.
Immune checkpoint therapy using a CTLA-4 inhibitor and an anti–PD-1 antibody is in ongoing clinical studies in patients with metastatic renal cell cancer. The PD-1 checkpoint inhibitor nivolumab was associated with an overall survival as long as 25 months in patients with renal cell cancer, said Eric Jonasch, MD, Associate Professor, Department of Genitourinary Medical Oncology, M.D. Anderson Cancer Center, Houston, TX., and a subset of patients had durable response to nivolumab in immune checkpoint therapy in renal cell cancer.
CTLA-4 inhibitors are associated with durable disease control in the first- and second-line settings for immune checkpoint therapy in metastatic melanoma cancer. In patients receiving CTLA-4 inhibitors in the second-line setting, "some of these patients have been followed for over 10 years without relapse for metastatic melanoma," said Anthony J. Olszanski, MD, RPh, Director, Medical Oncology Melanoma Program, Fox Chase Cancer Center, Philadelphia.
With the development of immune checkpoint therapy in cancer, More proofs will be found to support the durable responses and long-term survival in various cancer for immune checkpoint therapy.
Wayne Kuznar et al. Immune Checkpoint Blockade Shows Durable Responses in Lung and Kidney Cancers, Metastatic Melanoma. VBCC 2015; 6:3.